3PO
This product is for research use only, not for human use. We do not sell to patients.
For small sizes, please check our retail website as below: www.invivochem.com
| Size | Price | Stock |
|---|---|---|
| 500mg | $450 | Check With Us |
| 1g | $650 | Check With Us |
| 5g | $1755 | Check With Us |
: Cat #: V2808 CAS #: 13309-08-5 Purity ≥ 98%
Description: 3PO [full/chemical name of 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one] is an inhibitor of the PFKFB3 (6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase).
Top Publications Citing Invivochem Products
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
| Molecular Weight (MW) | 210.24 |
|---|---|
| Molecular Formula | C13H10N2O |
| CAS No. | 13309-08-5 |
| Storage | -20℃ for 3 years in powder formrrrr |
| -80℃ for 2 years in solvent | |
| Solubility In Vitro | DMSO: > 10 mMrrrr |
| Water: < 1mg/mLrr (Insoluble)rr | |
| Ethanol: < 1mg/mL | |
| SMILES Code | O=C(C1=CC=NC=C1)/C=C/C2=CC=CN=C2 |
| Synonyms | 3PO; 3-PO; 3 PO |
| Protocol | In Vitro | The ability of 3PO to inhibit glycolysis was confirmed in the present study. Indeed, by using Seahorse technology, 3PO inhibits glycolysis in a concentration-dependent manner in HUVECs, resulting in an up to 50% reduction in glycolytic rate. Moreover, 3PO inhibits capillary tube formation, migration of ECs, and formation of aortic sprouts, which are all processes that heavily depend on glycolysis. |
|---|---|---|
| In Vivo | In line with this statement, experimental evidence from the present study indicates that treatment of ApoE−/− mice with 3PO for 4 weeks caused neither substantial adverse effects nor changes in general metabolism. Reduced food intake was observed, yet circulating liver enzymes, blood glucose, insulin, and total cholesterol were not affected. Also a glucose and insulin tolerance test was perfectly normal. However, 3PO caused a decrease in the level of circulating triglycerides and a significant rise in β-hydroxybutyrate levels, indicating a metabolic switch from glucose to fatty acid–derived ketones to provide sufficient energy. |
These protocols are for reference only. InvivoChem does not
independently validate these methods.
| Solvent volume to be added | Mass (the weight of a compound) | |||
|---|---|---|---|---|
| Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
| 1mM | 4.7565 mL | 23.7823 mL | 47.5647 mL | 95.1294 mL |
| 5mM | 0.9513 mL | 4.7565 mL | 9.5129 mL | 19.0259 mL |
| 10mM | 0.4756 mL | 2.3782 mL | 4.7565 mL | 9.5129 mL |
| 20mM | 0.2378 mL | 1.1891 mL | 2.3782 mL | 4.7565 mL |
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
=
Concentration
×
Volume
×
Molecular Weight*
The dilution calculator equation
Concentration(start)
×
Volume(start)
=
Concentration(final)
×
Volume(final)
This equation is commonly abbreviated as: C1 V1 = C2 V2
Concentration(start)
C1
×
Volume(start)
V1
=
Concentration(final)
C2
×
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg
Average weight of animals g
Dosing volume per animal µL
Number of animals
Step Two: Enter the in vivo formulation
%DMSO
+
%
+
%Tween 80
+
%ddH2O
Calculation Results:
Working concentration:
mg/ml;
Method for preparing DMSO master liquid:
mg
drug pre-dissolved in
µL
DMSO(Master liquid concentration
mg/mL)
,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:
Take
µL
DMSO master liquid, next add
µL
PEG300, mix and clarify, next add
µL
Tween 80,mix and clarify, next add
µL
ddH2O,mix and clarify.
Note:
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.